Market closedNon-fractionalADR
Novo Nordisk/NVO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Novo Nordisk
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Ticker
NVO
Sector
Healthcare
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Bagsvaerd, Denmark
Employees
66,015
Website
www.novonordisk.com
Novo Nordisk Metrics
BasicAdvanced
$569B
Market cap
44.14
P/E ratio
$2.90
EPS
0.15
Beta
$1.37
Dividend rate
1.07%
Dividend yield
Price and volume
Market cap
$569B
Beta
0.15
Dividend rate
$1.37
Financial strength
Current ratio
0.703
Quick ratio
0.489
Long term debt to equity
16.949
Total debt to equity
27.224
Dividend payout ratio (TTM)
47.03%
Interest coverage (TTM)
204.48%
Management effectiveness
Return on assets (TTM)
25.24%
Return on equity (TTM)
99.87%
Valuation
Price to earnings (TTM)
44.143
Price to revenue (TTM)
16.094
Price to book
39.74
Price to tangible book (TTM)
100.1
Price to free cash flow (TTM)
78.143
Dividend yield (TTM)
1.07%
Growth
Revenue change (TTM)
29.72%
Earnings per share change (TTM)
47.53%
3-year revenue growth (CAGR)
24.40%
3-year earnings per share growth (CAGR)
29.35%
3-year dividend per share growth (CAGR)
27.36%
What the Analysts think about Novo Nordisk
Analyst Ratings
Majority rating from 10 analysts.
Novo Nordisk Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Novo Nordisk Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Novo Nordisk News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $569B as of July 26, 2024.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 44.14 as of July 26, 2024.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of July 26, 2024, the dividend rate is $1.3676 and the yield is 1.07%. Novo Nordisk has a payout ratio of 47.03% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Novo Nordisk stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.